Roth Capital Starts Intec Pharma Ltd. (NTEC) at Buy

Roth Capital initiates coverage on Intec Pharma Ltd. (NASDAQ: NTEC) with a Buy rating and a price target of $9.50.

Analyst Michael Higgins commented, "As drug delivery innovation has turned towards non-oral methods, the opportunity for oral technologies grows. Intec Pharma is a specialty pharmaceutical company that is developing its pipeline around its Accordion Pill platform technology."

The analyst highlighted:

• Intec’s lead asset is AP-CDLD, a Phase 3-ready, gastro-retentive capsule with carbidopa/levodopa for Parkinson’s disease.
• Don’t yawn! Intec’s second pipeline asset, AP-ZP (zaleplon), offers an alternative to a zolpidem-heavy (Ambien) Rx insomnia market.

NOTE: The company completed an IPO August 4, 2015. ROTH Capital Partners served as a joint book-running manager for the offering."

For an analyst ratings summary and ratings history on Intec Pharma Ltd. click here. For more ratings news on Intec Pharma Ltd. click here.

Shares of Intec Pharma Ltd. closed at $5.65 yesterday.

You May Also Be Interested In

• Citizens Starts MARA Holdings Inc (MARA) at Market Outperform
• Barclays Starts Sigma Foods SAB DE CV (SIGMAFA:MM) at Overweight
• Goldman Sachs Starts Twilio (TWLO) at Buy